Download PDF
Horm Metab Res 2014; 46(03): 219-223
DOI: 10.1055/s-0033-1358730
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Metabolic Parameters and Adipokine Profile in Growth Hormone Deficient (GHD) Children Before and After 12-Month GH Treatment

C. Meazza   *
1   Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
H. H. Elsedfy   *
2   Paediatrics Department, Ain Shams University, Cairo, Egypt
,
S. Pagani
1   Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
E. Bozzola
3   Pediatric and Infectious Disease Unit, Department of Pediatrics, Bambino Gesù Children’s Hospital, Rome, Italy
,
M. El Kholy   #
2   Paediatrics Department, Ain Shams University, Cairo, Egypt
,
M. Bozzola   #
› Author Affiliations
Further Information

Publication History

received 24 July 2013

accepted 21 October 2013

Publication Date:
02 December 2013 (online)

Also available at
    Permissions and Reprints

Abstract

It is a common knowledge that GH exhibits a large number of metabolic effects, involving lipid and glucose homeostasis. The aim of the study was to investigate the effect of one year GH therapy on metabolic parameters and adipokines in GH deficient (GHD) children. Sixteen prepubertal children (11 M and 5 F) with complete GHD (age range: 3.4–14.7 years) and 20 (13 M and 7 F) age and sex-matched healthy children (age range: 4.6–12.3 years) were studied. Blood was collected from patients before starting GH therapy (0.025 mg/kg/day) and one year later, and from healthy children to measure adiponectin, leptin, osteoprotegerin, resistin, interleukin (IL)-6, tumor necrosis factor (TNF)-α levels, and other glucose and lipid metabolism parameters. Adiponectin and resistin levels were significantly higher (49 980 ng/ml vs. 14 790 ng/ml and 11.0 pg/ml vs. 6.3, respectively) in GHD children before GH therapy than in controls. Serum IGF-I levels (p=0.0001) and height SDS (p<0.0001) significantly increased after 12 months’ of GH therapy. There was a loss of body fat reflected by a significant decline in tricep (p=0.0003) and subscapular skinfold thickness SDS (p=0.0023). After 12 months, there was a significant rise in insulin (p=0.0052) and leptin levels (p=0.0048) and a significant decrease in resistin (p=0.0312) and TNF-α (p=0.0137). We observed that lipid and glucose metabolisms are only slightly affected in GHD children. Growth hormone replacement therapy affects some factors, such as leptin, resistin and fat mass, suggesting that also in children, GH treatment has a role in the regulation of factors secreted by adipose tissue.

Key words

GH deficiency - GH therapy - adipokines - metabolism - children

* The first 2 authors contributed equally to the writing of the manuscript.


# Last 2 authors should be considered joint last authors.


 

  • References

  • 1 Capalbo D, Esposito A, Di Mase R, Barbieri F, Parenti G, Vajro P, Pignata C, Salerno M. Update on early cardiovascular and metabolic risk factors in children and adolescents affected with growth hormone deficiency. Minerva Endocrinol 2012; 37: 379-389
    PubMedGoogle Scholar
  • 2 Decker R, Albertsson-Wikland K, Kriström B, Nierop AF, Gustafsson J, Bosaeus I, Fors H, Hochberg Z, Dahlgren J. Metabolic outcome of GH treatment in prepubertal short children with and without classical GH deficiency. Clin Endocrinol (Oxf) 2010; 73: 346-354
    CrossrefPubMedGoogle Scholar
  • 3 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
    CrossrefPubMedGoogle Scholar
  • 4 Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines-energy regulation from the human perspective. J Nutr 2006; 136: 1935S-1939S
    PubMedGoogle Scholar
  • 5 Gherman CD, Mironiuc AI. Evaluation of serum adipokines in peripheral arterial occlusive disease. Mediators Inflamm 2012; 2012: 257808
    PubMedGoogle Scholar
  • 6 Egecioglu E, Bjursell M, Ljungberg A, Dickson SL, Kopchick JJ, Bergström G, Svensson L, Oscarsson J, Törnell J, Bohlooly-Y M. Growth hormone receptor deficiency results in blunted ghrelin feeding response, obesity, and hypolipidemia in mice. Am J Physiol Endocrinol Metab 2006; 290: E317-E325
    PubMedGoogle Scholar
  • 7 Berryman DE, List EO, Sackmann-Sala L, Lubbers E, Munn R, Kopchick JJ. Growth hormone and adipose tissue: beyond the adipocyte. Growth Horm IGF Res 2011; 21: 113-123
    CrossrefPubMedGoogle Scholar
  • 8 Brooks AJ, Wooh JW, Tunny KA, Waters MJ. Growth hormone receptor; mechanism of action. Int J Biochem Cell Biol 2008; 40: 1984-1989
    CrossrefPubMedGoogle Scholar
  • 9 Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30: 152-177
    CrossrefPubMedGoogle Scholar
  • 10 Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity and weight velocity: British children, 1965 part II. Arch Dis Child 1966; 41: 613-635
    CrossrefPubMedGoogle Scholar
  • 11 Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45: 13-23
    CrossrefPubMedGoogle Scholar
  • 12 Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44: 291-303
    CrossrefPubMedGoogle Scholar
  • 13 Waaler PE. Anthropometric studies in Norwegian children. Acta Paediatr Scand Suppl 1983; 308: 1-41
    PubMedGoogle Scholar
  • 14 Cianfarani S, Maiorana A, Geremia C, Scirè G, Spadoni GL, Germani D. Blood glucose concentrations are reduced in children born small for gestational age (SGA), and thyroid-stimulating hormone levels are increased in SGA with blunted post-natal catch-up growth. J Clin Endocrinol Metab 2003; 88: 2699-2705
    CrossrefPubMedGoogle Scholar
  • 15 Ciresi A, Amato MC, Criscimanna A, Mattina A, Vetro C, Galluzzo A, D’Acquisto G, Giordano C. Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol 2007; 156: 353-360
    CrossrefPubMedGoogle Scholar
  • 16 Saenger P. Metabolic consequences of growth hormone treatment in paediatric practice. Horm Res 2000; 53: 60-69
    CrossrefPubMedGoogle Scholar
  • 17 Makimura H, Stanley T, Mun D, Chen C, Wei J, Connelly JM, Hemphill LC, Grinspoon SK. Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity. J Clin Endocrinol Metab 2009; 94: 5131-5138
    CrossrefPubMedGoogle Scholar
  • 18 van der Sluis IM, Boot AM, Hop WC, De Rijke YB, Krenning EP, de Muinck Keizer-Schrama SM. Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: a 6-year follow-up study. Horm Res 2002; 58: 207-214
    CrossrefPubMedGoogle Scholar
  • 19 López-Siguero JP, López-Canti LF, Espino R, Caro E, Fernández-García JM, Gutiérrez-Macías A, Rial JM, Lechuga JL, Macías F, Martínez-Aedo MJ, Rico S, Rodríguez I, Guillén J, Arroyo FJ, Bernal S, Espigares R, Núñez M, Escribano A, Barrionuevo JL, Gentil J, Barrios V, Fernández-Nistal A, Martos-Moreno GA, Martínez V, Argente J. Effect of recombinant growth hormone on leptin, adiponectin, resistin, interleukin-6, tumor necrosis factor-α and ghrelin levels in growth hormone-deficient children. J Endocrinol Invest 2011; 34: 300-306
    PubMedGoogle Scholar
  • 20 Bozzola M, Meazza C. Adipose tissue, its hormones and infant development. In: Watson RR, Grimble G, Preedy VR, Zibadi S. (eds.). Nutrition in Infancy: Volume 2, Nutrition and Health. New York: Springer Science+Business Media; 2013: 321-330
    CrossrefGoogle Scholar
  • 21 Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455
    CrossrefPubMedGoogle Scholar
  • 22 Oliveira CR, Salvatori R, Meneguz-Moreno RA, Aguiar-Oliveira MH, Pereira RM, Valença EH, Araujo VP, Farias NT, Silveira DC, Vieira JG, Barreto-Filho JA. Adipokine profile and urinary albumin excretion in isolated growth hormone deficiency. J Clin Endocrinol Metab 2010; 95: 693-698
    CrossrefPubMedGoogle Scholar
  • 23 Khosla S. The OPG/RANKL/RANK system. Endocrinology 2001; 142: 5050-5055
    CrossrefPubMedGoogle Scholar
  • 24 Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner’s syndrome and rheumatoid arthritis. Clin Endocrinol 2004; 60: 87-91
    CrossrefPubMedGoogle Scholar
  • 25 Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843
    CrossrefPubMedGoogle Scholar
  • 26 Pagani S, Meazza C, Travaglino P, De Benedetti F, Tinelli C, Bozzola M. Serum cytokine levels in GH-deficient children during substitutive GH therapy. Eur J Endocrinol 2005; 152: 207-210
    CrossrefPubMedGoogle Scholar
  • 27 Cañete R, Valle M, Martos R, Sánchez-Carrión A, Cañete MD, van Donkelaar EL. Short-term effects of GH treatment on coagulation, fibrinolysis, inflammation biomarkers, and insulin resistance status in prepubertal children with GH deficiency. Eur J Endocrinol 2012; 167: 255-260
    PubMedGoogle Scholar